ÈËÆÞÖгöÊÓƵ

Aaron M. Secrest
( out of 35 reviews )

Aaron M. Secrest, MD, PhD, MBA

Languages spoken: English

  • Aaron Secrest, MD, PhD, MBA, is currently on a two-year sabbatical working as a senior medical officer in dermatology at Christchurch Hospital in New Zealand to experience a quality national healthcare system firsthand. He is temporarily stepping away from routine clinical care at Farmington ÈËÆÞÖгöÊÓƵ Center and the ÈËÆÞÖгöÊÓƵ Hospital outpatient clinic. He will continue to staff Rapid Access Dermatology clinic (urgent care for skin issues) when in the US.

    His particular focus is understanding what matters most to his patients and how his patients' skin issues affect their quality of life. To help him, Dr. Secrest encourages his patients to complete a quality of life assessment called Skindex-16 at every visit. Skindex-16 asks questions to help Dr. Secrest and his patients understand how their skin issues are affecting their symptoms, their emotions, and their ability to function. Skindex-16 is particularly useful because it helps Dr. Secrest track how his patients feel their skin issues are doing - are they getting better or worse over time His patients can request copies of their Skindex-16 scores at any time to see how they are doing.

    Dr. Secrest completed an MBA in 2020 at the ÈËÆÞÖгöÊÓƵ of Utah to help him understand the business side of medicine to try to find ways to help improve how healthcare works in the U.S. Dr. Secrest is keenly aware of how insurances are changing over the years, and often, patients are required to pay for more of their care and their treatments out-of-pocket. Dr. Secrest spends time trying to identify the most cost-effective care for his patients, even if that means the best treatment is over-the-counter. Please let Dr. Secrest know if you have a high-deductible plan, so he can ensure you get the best value out of your care.

    Dr. Secrest recently stepped down as Vice Chair of Business Strategy for Dermatology but remains as an Adjunct Assistant Professor in the Departments of Dermatology and Population ÈËÆÞÖгöÊÓƵ Sciences at the ÈËÆÞÖгöÊÓƵ of Utah, where, in addition to seeing patients, he does research on quality of life, access to care, and costs of care in dermatology. He is board-certified in dermatology and a member of both the American Academy of Dermatology and the Society for Pediatric Dermatology. He completed an intern year at Cincinnati Children's Hospital prior to his dermatology training at the ÈËÆÞÖгöÊÓƵ of Utah, where he served as a chief resident.

    Specialties

    Board Certification

    American Board of Dermatology

    Patient Rating

    4.9 /5
    ( out of 35 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 31, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Very courteous and personable. Listens to your concerns and answers questions throughly and thoughtfully.

    October 29, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Secrest was friendly, informative, and professional. I will be using him as my dermatologist going forward.

    October 29, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Very professional and caring

    October 22, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr Secrest is thorough, very skillful, extremely kind and personable. He's one of the best doctors I have ever encountered.

    March 21, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Great care and great expertise.

    March 20, 2024
    UH HOSPITALS AND CLINICS

    Dr. Secrest and his staff are so great! They helped my daughter and I feel very comfortable and at ease during our clinic visit.

    March 19, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Secrest listened to my concerns and explained in great detail helpful information. Highly recommend!

    March 14, 2024
    UH HOSPITALS AND CLINICS

    Dr. Secrest is skillfull, thorough, kind and caring. He is exemplary in every way, and I cannot recommend him highly enough.

    March 14, 2024
    UH HOSPITALS AND CLINICS

    great care, thanks

    See More Patient Comments

  • Aaron Secrest, MD, PhD, MBA, is currently on a two-year sabbatical working as a senior medical officer in dermatology at Christchurch Hospital in New Zealand to experience a quality national healthcare system firsthand. He is temporarily stepping away from routine clinical care at Farmington ÈËÆÞÖгöÊÓƵ Center and the ÈËÆÞÖгöÊÓƵ Hospital outpatient clinic. He will continue to staff Rapid Access Dermatology clinic (urgent care for skin issues) when in the US.

    His particular focus is understanding what matters most to his patients and how his patients' skin issues affect their quality of life. To help him, Dr. Secrest encourages his patients to complete a quality of life assessment called Skindex-16 at every visit. Skindex-16 asks questions to help Dr. Secrest and his patients understand how their skin issues are affecting their symptoms, their emotions, and their ability to function. Skindex-16 is particularly useful because it helps Dr. Secrest track how his patients feel their skin issues are doing - are they getting better or worse over time His patients can request copies of their Skindex-16 scores at any time to see how they are doing.

    Dr. Secrest completed an MBA in 2020 at the ÈËÆÞÖгöÊÓƵ of Utah to help him understand the business side of medicine to try to find ways to help improve how healthcare works in the U.S. Dr. Secrest is keenly aware of how insurances are changing over the years, and often, patients are required to pay for more of their care and their treatments out-of-pocket. Dr. Secrest spends time trying to identify the most cost-effective care for his patients, even if that means the best treatment is over-the-counter. Please let Dr. Secrest know if you have a high-deductible plan, so he can ensure you get the best value out of your care.

    Dr. Secrest recently stepped down as Vice Chair of Business Strategy for Dermatology but remains as an Adjunct Assistant Professor in the Departments of Dermatology and Population ÈËÆÞÖгöÊÓƵ Sciences at the ÈËÆÞÖгöÊÓƵ of Utah, where, in addition to seeing patients, he does research on quality of life, access to care, and costs of care in dermatology. He is board-certified in dermatology and a member of both the American Academy of Dermatology and the Society for Pediatric Dermatology. He completed an intern year at Cincinnati Children's Hospital prior to his dermatology training at the ÈËÆÞÖгöÊÓƵ of Utah, where he served as a chief resident.

    Board Certification and Academic Information

    Academic Departments Dermatology -Primary
    Population ÈËÆÞÖгöÊÓƵ Sciences -Adjunct
    Board Certification
    American Board of Dermatology

    Education history

    Graduate Training Eccles School of Business - ÈËÆÞÖгöÊÓƵ of Utah M.B.A.
    Dermatology - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Chief Resident
    Residency Dermatology - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Resident
    Pediatrics - Cincinnati Children’s Hospital Medical Center Intern/Resident
    Doctoral Training Epidemiology - ÈËÆÞÖгöÊÓƵ of Pittsburgh Ph.D.
    Epidemiology - ÈËÆÞÖгöÊÓƵ of Pittsburgh M.P.H.
    Professional Medical Medicine - ÈËÆÞÖгöÊÓƵ of Pittsburgh M.D.
    Major: Microbiology: Minors: Asian Studies, Business Management - Brigham Young ÈËÆÞÖгöÊÓƵ B.S.

    Selected Publications

    Journal Article

    1. Hopkins ZH, Jimenez A, Taliercio VL, Clarke JT, Hansen CB, Hull CM, Rhoads JLW, Zone JJ, Sahni VN, Kean J, Secrest AM (2024). Skin-Related Quality of Life During Autoimmune Bullous Disease Course. JAMA Dermatol, 159(11), 1185-1194. ()
    2. Snyder AM, Taliercio VL, Rich BE, Brandenberger AU, Webber LB, Biber JE, Hess R, Rhoads JL, Secrest AM (2023). Quality of Life and Avoiding Triggers of Atopic Dermatitis Flares: A Qualitative Study. Skinmed, 21(4), 233-235. ()
    3. Hopkins Z, Diaz O, Kaprive JF, Carlisle R, Moreno C, Bommareddy K, Sheikh N, Frost Z, Akhtar A, Secrest AM (2023). Methods Reporting Quality and its Association with Methods Section Length: A Cross-sectional Assessment of STROBE and CONSORT Reporting Adherence in Top-cited Dermatology Journals. J Clin Aesthet Dermatol, 16(7), 54-62. ()
    4. Snyder AM, Taliercio VL, Brandenberger AU, Rich BE, Webber LB, Beshay AP, Biber JE, Hess R, Rhoads JLW, Secrest AM (2023). Atopic Dermatitis: A Qualitative Study on the Burdens of Living with Itchiness. J Clin Aesthet Dermatol, 16(7), 22-25. ()
    5. Simister S, Flint N, Webb J, Nyarko O, Secrest A, Lewis B, Dickerson T (2023). Exploring the knowledge, attitude, and practices of over-the-counter medical sellers in Ghana. J Public ÈËÆÞÖгöÊÓƵ Afr, 14(4), 2122. ()
    6. Kuceki G, Snyder AM, Hopkins ZH, Secrest AM (2023). A survey of United States dermatologists' knowledge, attitudes, and practices with intramuscular triamcinolone. Arch Dermatol Res. ()
    7. Snyder AM, Chen SC, Chren MM, Ferris LK, Edwards LD, Swerlick RA, Flint ND, Cizik AM, Hess R, Kean J, Secrest AM, Dermatology PRO Consortium (2023). Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology. Am J Clin Dermatol, 24(4), 1-13. ()
    8. Kern JA, Amanullah AA, Sahni DR, Mathis JG, Hull CM, Powell DL, Secrest AM (2023). Granulomatous cheilitis - is there a role for allergen screening and avoidance? J Dermatolog Treat, 34(1), 1-3. ()
    9. Elkeeb DM, Hopkins ZH, Bolender CM, Moreno C, Florell SR, Bowen AR, Vitale P, Zussman J, Duffy K, Grossman D, Secrest AM, Wada DA (2022). A Single-Institution Cohort Study With Nevi of Special Site: Recurrence, Progression to Melanoma, and Patterns of Management. Am J Dermatopathol, 45(1), 28-39. ()
    10. Hopkins ZH, Kuceki G, Taliercio VL, Snyder AM, Stoddard GJ, Duffin KC, Hess R, Secrest AM (2022). Evaluation of Skindex-16 construct validity in routinely collected psoriasis data: a retrospective analysis of the relationship between overall physician global assessment scores and Skindex-16 and measure discordance. Arch Dermatol Res. ()
    11. Snyder AM, Brandenberger AU, Taliercio VL, Rich BE, Webber LB, Beshay AP, Biber JE, Hess R, Rhoads JLW, Secrest AM (2022). Quality of Life Among Family of Patients with Atopic Dermatitis and Psoriasis. Int J Behav Med. ()
    12. Amanullah AA, Sahni DR, Sahni VN, Hull CM, Powell DL, Secrest AM (2022). Reply to: current treatment modalities in granulomatous cheilitis. Int J Dermatol. ()
    13. Secrest AM, Chren MM (2022). Incorporating patient-reported outcomes as a vital sign for dermatologic clinical care and clinical investigations. J Invest Dermatol, 142, 1529-1532. ()
    14. Clark JJ, Snyder AM, Sreekantaswamy SA, Petersen MJ, Lewis BKH, Secrest AM, Florell SR (2021). Dermatologic care of incarcerated patients: A single-center descriptive study of teledermatology and face-to-face encounters. J Am Acad Dermatol, 85(6), 1660-1662. ()
    15. Ma B, Sahni V, Sahni D, Secrest A (2021). Disseminate and Recurrent Infundibulofolliculitis: An Under-Recognized Yet Treatable Entity. J Drugs Dermatol, 20(12), 1353-1354. ()
    16. Hopkins ZH, Carlisle RP, Frost ZE, Curtis JA, Ferris LK, Secrest AM (2022). Risk Factors and Predictors of Survival Among Patients with Amelanotic Melanoma Compared to Melanotic Melanoma in the National Cancer Database. J Clin Aesthet Dermatol, 14(12), 36-43. ()
    17. Taliercio VL, Snyder AM, Biggs AM, Kean J, Hess R, Duffin KC, Cizik AM, Secrest AM (2021). Clinicians' perspectives on the integration of electronic patient-reported outcomes into dermatology clinics: a qualitative study. Qual Life Res, 31(6), 1719-1725. ()
    18. Sahni VN, Dao DP, Sahni DR, Secrest AM (2021). Lichen spinulosus: insights into treatment. Dermatol Online J, 27(10). ()
    19. Snyder AM, Taliercio VL, Brandenberger AU, Rich BE, Webber LB, Beshay AP, Biber JE, Hess R, Rhoads JLW, Secrest AM (2021). Effects of Pain From Atopic Dermatitis: Interview and Focus Group Study With Patients and Their Families. JMIR Dermatol, 4(2), e29826. ()
    20. Flint ND, Rhoads JLW, Carlisle R, Ferrel M, Hopkins ZH, Secrest AM (2021). The continued inappropriate use and overuse of combination topical clotrimazole-betamethasone. Dermatol Online J, 27(8). ()
    21. Anderson A, Matsumoto M, Secrest A, Saul MI, Ho J, Ferris LK (2022). Cost of Treatment of Benign and Premalignant Lesions During Skin Cancer Screening. JAMA Dermatol, 157(7), 876-879. ()
    22. Flint ND, Simister S, Secrest AM (2021). Usefulness of an Inexpensive, Battery-Powered, Handheld Microscope in Low-Resource Dermatologic Practices. Indian Dermatol Online J, 12(4), 645-646. ()
    23. Taliercio VL, Snyder AM, Webber LB, Langner AU, Rich BE, Beshay AP, Ose D, Biber JE, Hess R, Rhoads JLW, Secrest AM (2021). The Disruptiveness of Itchiness from Psoriasis: A Qualitative Study of the Impact of a Single Symptom on Quality of Life. J Clin Aesthet Dermatol, 14(6), 42-48. ()
    24. Kennedy J, Arey S, Hopkins Z, Tejasvi T, Farah R, Secrest AM, Lipoff JB (2022). Dermatologist Perceptions of Teledermatology Implementation and Future Use After COVID-19: Demographics, Barriers, and Insights. JAMA Dermatol, 157(5), 595-597. ()
    25. Taliercio V, Langner AU, Secrest AM, Duffin KC (2021). Assessing psoriasis severity: psychometric validation of overall physician global assessment (OPGA). J Am Acad Dermatol, 86(3), 637-638. ()
    26. Flint ND, Bishop MD, Smart TC, Strunck JL, Boucher KM, Grossman D, Secrest AM (2020). Low accuracy of self-reported family history of melanoma in high-risk patients. Fam Cancer, 20(1), 41-48. ()
    27. Secrest AM, Hopkins ZH, Frost ZE, Taliercio VL, Edwards LD, Biber JE, Chen SC, Chren MM, Ferris LK, Kean J, Hess R, Dermatology PRO Consortium (2020). Quality of Life Assessed Using Skindex-16 Scores Among Patients With Acne Receiving Isotretinoin Treatment. JAMA Dermatol, 156(10), 1098-1106. ()
    28. Carlisle RP, Flint ND, Hopkins ZH, Eliason MJ, Duffin KC, Secrest AM (2020). Administrative Burden and Costs of Prior Authorizations in a Dermatology Department. JAMA Dermatol, 156(10), 1074-1078. ()
    29. Laggis CW, Secrest AM, Agyei M, Simister S, Davis AN, Dickerson T, Rhoads JL (2020). The Impact of Skin Disease on Quality of Life in Rural Communities of Ghana. 4(5), 417-423.
    30. Strunck JL, Smart TC, Boucher KM, Secrest AM, Grossman D (2020). Improved melanoma outcomes and survival in patients monitored by total body photography: A natural experiment. J Dermatol, 47(4), 342-347. ()
    31. Gaufin M, Hess R, Hopkins ZH, Biber JE, Secrest AM (2019). Practical screening for depression in dermatology: using technology to improve care. Br J Dermatol, 182(3), 786-787. ()
    32. Hopkins ZH, Moreno C, Secrest AM (2020). Influence of Social Media on Cosmetic Procedure Interest. J Clin Aesthet Dermatol, 13(1), 28-31. ()
    33. Hopkins ZH, Secrest AM (2019). Public ÈËÆÞÖгöÊÓƵ Implications of Google Searches for Sunscreen, Sunburn, Skin Cancer, and Melanoma in the United States. Am J ÈËÆÞÖгöÊÓƵ Promot, 33(4), 611-615. ()
    34. Hopkins ZH, Moreno C, Secrest AM (2019). Lack of confidence interval reporting in dermatology: a call to action. Br J Dermatol, 180(4), 910-915. ()
    35. Hopkins ZH, Secrest AM (2019). An international comparison of Google searches for sunscreen, sunburn, skin cancer, and melanoma: Current trends and public health implications. Photodermatol Photoimmunol Photomed, 35(2), 87-92. ()
    36. Grossman D, Farnham JM, Hyngstrom J, Klapperich ME, Secrest AM, Empey S, Bowen GM, Wada D, Andtbacka RHI, Grossmann K, Bowles TL, Cannon-Albright LA (2018). Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011). J Am Acad Dermatol, 79(2), 238-244. ()
    37. Anderson AM, Matsumoto M, Saul MI, Secrest AM, Ferris LK (2018). Accuracy of Skin Cancer Diagnosis by Physician Assistants Compared With Dermatologists in a Large ÈËÆÞÖгöÊÓƵ Care System. JAMA Dermatol, 154(5), 569-573. ()
    38. Matsumoto M, Secrest A, Anderson A, Saul MI, Ho J, Kirkwood JM, Ferris LK (2018). Estimating the cost of skin cancer detection by dermatology providers in a large health care system. J Am Acad Dermatol, 78(4), 701-709.e1. ()
    39. Secrest AM, Asgari MM, Kourosh AS, Barbieri JS, Albrecht J (2017). Prior authorizations for dermatologic medications: An American Academy of Dermatology survey of US dermatology providers and staff. J Am Acad Dermatol, 77(4), 784-786. ()
    40. Andrulonis R, Secrest AM, Patton TJ, Grandinetti LM, Ferris LK (2017). A cross-sectional study of indoor tanning use among patients seeking skin cancer screening. J Am Acad Dermatol, 76(1), 164-165. ()
    41. Houston NA, Secrest AM, Harris RJ, Mori WS, Eliason MJ, Phillips CM, Ferris LK (2016). Patient Preferences During Skin Cancer Screening Examination. JAMA Dermatol, 152(9), 1052-4. ()
    42. Clark JJ, Secrest AM, Hull CM, Eliason MJ, Leiferman KM, Gleich GJ, Powell DL (2016). The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: Retrospective chart review. J Am Acad Dermatol, 74(6), 1274-6. ()
    43. Saluja SS, Secrest AM, Florell SR (2016). Acute Presentation of Tender Papules and Plaques in a Patient With Leukemia. JAMA Dermatol, 152(5), 571-2. ()
    44. Miller RG, Secrest AM, Sharma RK, Songer TJ, Orchard TJ (2012). Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes, 61(11), 2987-92. ()
    45. McGuire ST, Secrest AM, Andrulonis R, Ferris LK (2011). Surveillance of patients for early detection of melanoma: patterns in dermatologist vs patient discovery. Arch Dermatol, 147(6), 673-8. ()
    46. Secrest AM, Costacou T, Gutelius B, Miller RG, Songer TJ, Orchard TJ (2011). Association of socioeconomic status with mortality in type 1 diabetes: the Pittsburgh epidemiology of diabetes complications study. Ann Epidemiol, 21(5), 367-73. ()
    47. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ (2011). Characterizing sudden death and dead-in-bed syndrome in Type 1 diabetes: analysis from two ÈËÆÞÖгöÊÓƵhood-onset Type 1 diabetes registries. Diabet Med, 28(3), 293-300. ()
    48. Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ (2010). All-cause mortality trends in a large population-based cohort with long-standing ÈËÆÞÖгöÊÓƵhood-onset type 1 diabetes: the Allegheny County type 1 diabetes registry. Diabetes Care, 33(12), 2573-9. ()
    49. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ (2010). Cause-specific mortality trends in a large population-based cohort with long-standing ÈËÆÞÖгöÊÓƵhood-onset type 1 diabetes. Diabetes, 59(12), 3216-22. ()
    50. Orchard TJ, Secrest AM, Miller RG, Costacou T (2010). In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia, 53(11), 2312-9. ()
    51. Andrulonis R, Secrest AM, McGuire ST, Geskin LJ, Ferris LK (2010). The influence of age and sex on reasons for seeking and expected benefits of skin cancer screening. Arch Dermatol, 146(10), 1097-102. ()

    Review

    1. Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, Secrest AM, Washington RE, Orchard TJ (2018). Mortality in Type 1 Diabetes. [Review]. ()
    2. Thomas LW, Elsensohn A, Bergheim T, Shiu J, Ganesan A, Secrest A (2018). Intramuscular Steroids in the Treatment of Dermatologic Disease: A Systematic Review. [Review]. J Drugs Dermatol, 17(3), 323-329. ()
    3. Collins MK, Secrest AM, Ferris LK (2014). Screening for melanoma. [Review]. Melanoma Res, 24(5), 428-36. ()

    Book Chapter

    1. Secrest AM, Washington RE, Orchard TJ (2017). Chapter 35. Mortality in type 1 diabetes. In Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE (Eds.), Diabetes in America (3rd, pp. 35.1-35.16). Bethesda, MD: National Institutes of ÈËÆÞÖгöÊÓƵ, NIH Pub No. 17-1468.

    Editorial

    1. Hopkins ZH, Han G, Tejasvi T, Deda LC, Goldberg R, Kennedy J, Arey S, Mathis JG, Balk R, Miller J, Secrest AM, Farah R, Lipoff JB (2022). Teledermatology During the COVID-19 Pandemic: Lessons Learned and Future Directions. Cutis, 109(1), 12-13. ()
    2. Secrest AM, Coman GC, Swink JM, Duffy KL (2021). Limiting Residency Applications to Dermatology Benefits Nearly Everyone. J Clin Aesthet Dermatol, 14(7), 30-32. ()
    3. Abuabara K, Asgari MM, Chen SC, Dellavalle RP, Kalia S, Secrest AM, Silverberg JI, Solomon JA, Weinstock MA, Wu JJ, Chren MM (2018 Aug). How data can deliver for dermatology. 79(2), 400-402.

    Letter

    1. Ali NS, Sahni VN, Ma BC, Sahni DR, Hull CM, Powell DL, Secrest AM (2021). Reply to: low response of granulomatous cheilitis to currently established treatments. [Letter to the editor]. J Eur Acad Dermatol Venereol, 35(12), e930-e931. ()
    2. Jensen NC, Snyder AM, Secrest AM, Mathis JG (2021). Retrospective review of IVIG use and cutaneous lupus in inflammatory autoimmune neuropathies: a case-cohort study. [Letter to the editor]. Int J Dermatol, 61, e445-e447. ()
    3. Ma BC, Sahni VN, Edwards LD, Sahni DR, Secrest AM (2021). Response to 'A call to standardize the BCC:SCC ratio'. [Letter to the editor]. Br J Dermatol, 185(4), 868-869. ()
    4. Truong A, Secrest AM, Zhang M, Forbes BR, Laggis CW, McFadden M, Gardner LJ, Powell DL, Lewis BKH (2020). A survey of dermatologic health-related quality of life and resource access in patients experiencing homelessness. [Letter to the editor]. J Am Acad Dermatol, 85(3), 775-778. ()
    5. Laggis CW, Lamb A, Secrest AM, Ufkes N, Halwani AS, Tao R, Gaffney D, Miles RR, Florell SR, Wada D (2020). Favourable outcomes in folliculotropic mycosis fungoides after multimodality treatment in a single institution. [Letter to the editor]. J Eur Acad Dermatol Venereol, 35(1), e42-e45. ()
    6. Truong A, Secrest AM, Fino NF, Laggis CW, Lewis BKH (2020). Homeless status and associations with treatment disparities for common skin conditions. [Letter to the editor]. Br J Dermatol, 183(3), 582-584. ()
    7. Truong A, Laggis CW, Annis TD, Secrest AM, Fino NF, Powell DL, Gardner LJ, Gregory T, Hull CM, Lewis BKH (2019). Factors associated with follow-up adherence in patients seen at a referral-based dermatology clinic for the homeless. [Letter to the editor]. J Am Acad Dermatol, 83(2), 629-631. ()
    8. Secrest AM, Chren MM, Hopkins ZH, Chen SC, Ferris LK, Hess R (2019). Benefits to patient care of electronically capturing patient-reported outcomes in dermatology. [Letter to the editor]. Br J Dermatol, 181(4), 826-827. ()
    9. Secrest AM, Elkeeb DM, Petron B, Elsensohn A, Edwards LD, Krueger GG, Duffin KC (2019). Systemic corticosteroid use in psoriasis: a national survey of board-certified dermatologists. [Letter to the editor]. J Eur Acad Dermatol Venereol, 33(3), e116-e117. ()

  • News & Podcasts

    News